,Canonical_Smiles,drug_name,drug_type,Label
0,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
1,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,NAT-Substrate,positive
2,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,4A11-Inducer,negative
3,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
4,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
5,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Ecabapide,-,negative
6,CC=O,acetaldehyde,2E1-Substrate,negative
7,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
8,C/C=C\C,cis_2_butene,2E1-Substrate,negative
9,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
10,C[C@@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,Labetalol,2D6-Inhibitor,negative
11,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
12,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,cerivastatin,3A4-Substrate,negative
13,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,Hydromorphone,2D6-Substrate,negative
14,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Hydrocortisone,GST-Inducer,negative
15,CC(C)[C@]12CC(=O)[C@@H](C)[C@H]1C2,beta_thujone,3A4-Substrate,negative
16,O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1,imidacloprid,2E1-Substrate,negative
17,CCN[C@@H]1C[C@H](N)[C@@H](O[C@@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,Netilmicin,NAT-Substrate,positive
18,CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Hydroquinidine,-,negative
19,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,CP2CI-Substrate,negative
20,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,Etoricoxib,2E1-Inhibitor,negative
21,CCCCCCCCCCCCCC(=O)O,myristic_acid,2E1-Substrate,negative
22,Clc1ccc([C@@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,Tioconazole,19A-Inhibitor,negative
23,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
24,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
25,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
26,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,Famciclovir,3A4-Substrate,negative
27,CC(C)(C)NC[C@H](O)c1cc(Cl)c(N)c(Cl)c1,Clenbuterol,1A2-Substrate,negative
28,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@H](O)C[C@H]1O,Alfacalcidol,Sterol_26_hydroxylase_Sterol_27_hydroxylase_Vitamin_D3_25_hydroxylase_5_beta_cholestane_3_alpha_7_alpha12_alpha_triol_27_hydroxylase-Substrate,negative
29,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
30,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,Saxagliptin,3A4-Substrate,negative
31,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
32,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,Clotiazepam,CP2CI-Substrate,negative
33,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
34,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
35,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,Liarozole,-,negative
36,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,flunarizine,2D6-Substrate,negative
37,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
38,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
39,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,Mosapride,-,negative
40,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
41,O=c1[nH]c(=O)n(C2CCCO2)cc1F,tegafur,2E1-Substrate,negative
42,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
43,COc1ccc(C(=O)[C@@H](C)N2CCCC2)cc1,MOPPP_R,2D6-Substrate,negative
44,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,Quinupristin/dalfopristin,3A4-Inhibitor,negative
45,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
46,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
47,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,Flunitrazepam,-,negative
48,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,19A-Inhibitor,negative
49,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
50,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,Tenoxicam,-,negative
51,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
52,COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Tetrabenazine,2D6-Inhibitor,negative
53,C[C@@]12CC[C@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@@H]3[C@@H]1CC[C@@H]2O,Estramustine,3A4-Substrate,negative
54,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
55,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,Levonorgestrel,19A-Inhibitor,negative
56,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
57,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSCCC(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,Desmopressin,Solute_carrier_family_12_member_1-Inducer,negative
58,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
59,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,Galantamine,2D6-Substrate,negative
60,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
61,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
62,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
63,C(=C/c1ccccc1)\c1ccccc1,trans_stilbene,2D6-Substrate,negative
64,CCCCCCCCC,nonane,2E1-Substrate,negative
65,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,Reboxetine,2D6-Inducer,negative
66,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,Zomepirac,3A4-Substrate,negative
67,Cc1cc(NC(=O)NC(=O)c2ccccc2N(C)C)ccc1Oc1ncc(Br)cn1,benzoyl_phenyl_urea,2D6-Substrate,negative
68,CC(CO)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,ipriflavone_M4,1A2-Substrate,negative
69,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,Ibutilide,-,negative
70,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,negative
71,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,negative
72,Clc1ccccc1CN1CCc2sccc2C1,Ticlopidine,2E1-Inhibitor,negative
73,O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,Isosorbide Mononitrate,3A4-Substrate,negative
74,CCC(C)(C)NCC(O)COc1ccccc1C(=O)CCc1ccccc1,Diprafenone,2D6-Substrate,negative
75,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,P450_HFLA-Substrate,negative
76,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,2E1-Substrate,negative
77,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
78,CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12,Pindolol,2D6-Substrate,negative
79,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
80,C[C@@H](O)[C@@H]1NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Octreotide,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
81,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,Delavirdine,2D6-Inhibitor,negative
82,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
83,CCCCOc1ccc2ccc(=O)oc2c1,7_butoxy_coumarin,3A4-Substrate,negative
84,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,negative
85,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,Cefoperazone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
86,OCCOCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Hydroxyzine,2D6-Inhibitor,negative
87,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,P450_HFLA-Substrate,negative
88,CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12,Terbinafine,19A-Inhibitor,negative
89,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
90,O=N[O-],Sodium Nitrite,GST-Inhibitor,negative
91,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
92,Cc1ncc([N+](=O)[O-])n1C[C@H](O)CCl,Ornidazole,P450_HFLA-Substrate,negative
93,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[C@@H](C(=O)N(C)C)N3)[C@H](C)[C@H]12,Meropenem,Solute_carrier_family_22_member_6-Substrate,negative
94,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Oxytocin,Solute_carrier_family_12_member_2-Inducer,negative
95,C1CNCCN1,Piperazine,2D6-Substrate,negative
96,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
97,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,Metoclopramide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
98,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
99,CCOc1ccc2ccccc2c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,Nafcillin,-,negative
100,COc1cc(Br)c2oc(C3CCNCC3)cc2c1,Brofaromine,2D6-Substrate,negative
101,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
102,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
103,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
104,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor,negative
105,CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,Drospirenone,-,negative
106,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
107,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,Ceftriaxone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
108,NC(N)=NN=Cc1c(Cl)cccc1Cl,Guanabenz,-,negative
109,c1ccc2c(c1)ccc1nc3ccc4ccccc4c3cc12,dibenzacridine,1A2-Substrate,negative
110,CN1CCCC1c1cccnc1,nicotine,2D6-Substrate,negative
111,COc1cc([C@H]2c3cc4c(cc3C[C@@H]3COC(=O)[C@H]32)OCO4)cc(OC)c1OC,Podophyllotoxin,2C19-Substrate,negative
112,C=C(C)c1ccc(OC)c(CN[C@H]2C3CCN(CC3)[C@H]2C(c2ccccc2)c2ccccc2)c1,ezlopitant_alkene_CJ_12_458,2D6-Substrate,negative
113,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
114,CCNc1nc(NC(C)C)nc(SC)n1,ametryne,2C19-Substrate,negative
115,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate,negative
116,COc1cc(-c2cc3c(c(=O)o2)C[C@]2(O)[C@](C)(CC[C@@]4(O)C(C)(C)C=CC(=O)[C@@]42C)O3)cc2c1OCO2,territrem_A,2D6-Substrate,negative
117,CC(NCC(O)COc1cccc2ccccc12)C(F)(F)F,trifluoro_propranolol,2D6-Substrate,negative
118,NC(=O)OCC(COC(N)=O)c1ccccc1,Felbamate,2E1-Substrate,negative
119,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Medroxyprogesterone,-,negative
120,CCC1CC2CC3c4[nH]c5ccc(OC)cc5c4CCN(C2)C13,12_methoxy_ibogamine,2D6-Substrate,negative
121,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb2,3A4-Substrate,negative
122,COC(C)(C)C,methyl_tert_butyl_ether,2E1-Substrate,negative
123,C=CCc1ccc2c(c1)OCO2,safrole,2E1-Substrate,negative
124,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Dihydrocodeine,2D6-Substrate,negative
125,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
126,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,apigenin,1A2-Substrate,negative
127,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
128,C[C@@H](NC(=Nc1ccncc1)NC#N)C(C)(C)C,Pinacidil,2D6-Substrate,negative
129,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2D6-Inhibitor,negative
130,CN(C)C(=N)NC(=N)N,Metformin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
131,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
132,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
133,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
134,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
135,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
136,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
137,CCCCCOc1ccc2ccc(=O)oc2c1,7_pentoxy_coumarin,3A4-Substrate,negative
138,CN(C)N=O,NN_dimethyl_nitrosoamine,2E1-Substrate,negative
139,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,Arbekacin,NAT-Substrate,positive
140,CCCCCCCC/C=C\CCCCCCCC(=O)O,oleic_acid,2E1-Substrate,negative
141,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,Cilostazol,2D6-Substrate,negative
142,O=C(c1cccs1)c1ccc(OCc2nnn[nH]2)c(Cl)c1Cl,tienilic_acid_newderiv_9,2C9-Substrate,negative
143,C=CC(C)(O)CCC=C(C)C,linalool,2D6-Substrate,negative
144,C=C(C)C1CO1,isoprene_epoxide_2,2E1-Substrate,negative
145,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
146,O=C(CO)NCCCOc1cccc(CN2CCCCC2)c1,Roxatidine,2D6-Substrate,negative
147,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,Sertraline,2D6-Inhibitor,negative
148,O=S1OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,endosulfan,2C19-Substrate,negative
149,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
150,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vindesine,-,negative
151,CC(Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,Tenofovir,-,negative
152,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,Triclosan,SUL-Inhibitor,negative
153,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,negative
154,COC(F)(F)C(Cl)Cl,Methoxyflurane,2E1-Substrate,negative
155,CSc1ccc2c(c1)N(CC[C@H]1CCCCN1C)c1ccccc1S2,thioridazine_R,2E1-Substrate,negative
156,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
157,Nc1nc(C(=CCC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@@H]23)cs1,Ceftibuten,Solute_carrier_family_15_member_1-Substrate,negative
158,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,Captopril,Methyltransferase-Substrate,negative
159,CC[C@H](Cc1ccc2c(c1)OCO2)NC,MBDB,2D6-Substrate,negative
160,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,Valdecoxib,2D6-Substrate,negative
161,CCCCNC(C)Cc1ccccc1,N_butyl_amphetamine,2D6-Substrate,negative
162,CN(CC(=O)O)C(=N)NP(=O)(O)O,Fosfocreatine,Methyltransferase-Inhibitor,negative
163,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
164,CCC(=O)C1(c2cccc(O)c2)CCN(C)CC1,Ketobemidone,2B6-Substrate,negative
165,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,Dofetilide,-,negative
166,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,Amoxapine,2D6-Substrate,negative
167,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Mitiglinide,UGT-Substrate,negative
168,O=NN(CCCl)C(=O)NCCCl,Carmustine,GST-Substrate,negative
169,CC(C)CCC[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3C[C@H](O)[C@]12C,5beta_cholestane_3alpha_7alpha_12alpha_triol,2C19-Substrate,negative
170,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,Rebamipide,-,negative
171,CC(=O)c1cc2cccc(OC[C@H](O)CNC(C)C)c2o1,Befunolol,2D6-Substrate,negative
172,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
173,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Sirolimus,P450_HFLA-Substrate,negative
174,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,Chlorpromazine,2E1-Inhibitor,negative
175,CCCCCCCCCCCCCCCCCC(=O)O,stearic_acid,2E1-Substrate,negative
176,CNCCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,desmethyl_citalopram,2D6-Substrate,negative
177,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
178,Oc1ccc(O)cc1,Hydroquinone,3A4-Substrate,negative
179,CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate,negative
180,CN1C(=O)CC(=O)N(c2ccc(O)cc2)c2cc(Cl)ccc21,4prime_hydroxy_clobazam,2C19-Substrate,negative
181,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor,negative
182,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,19A-Inhibitor,negative
183,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,Melphalan,GST-Substrate,negative
184,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
185,Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfatroxazole,-,negative
186,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
187,O=C(O)C=Cc1ccccc1,Bemiparin,SUL-Substrate,negative
188,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
189,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
190,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
191,CCN(CC)CC#CCOC(=O)[C@@](O)(c1ccccc1)C1CCCCC1,Oxybutynin,2D6-Inhibitor,negative
192,CCCN1CCCC2Cc3nc(N)ncc3CC21,Quinelorane,-,negative
193,CN(CCCC(=O)c1cccnc1)N=O,NNK,2E1-Substrate,negative
194,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,Levothyroxine Sodium,3A4-Substrate,negative
195,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1,Venlafaxine,2D6-Inhibitor,negative
196,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
197,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
198,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
199,CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,Efonidipine,-,negative
200,CCCCCCCCCCCC(=O)O,lauric_acid,2E1-Substrate,negative
201,O=C(c1cccs1)c1ccc(O)c(Cl)c1Cl,tienilic_acid_deriv_1,2C9-Substrate,negative
202,CCCCN(CCCC)N=O,NN_dibutyl_nitrosoamine,2E1-Substrate,negative
203,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
204,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer,negative
205,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,-,negative
206,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
207,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,4A11-Inducer,negative
208,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,4A11-Inducer,negative
209,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Vorinostat,Methyltransferase-Inhibitor,negative
210,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
211,CNS(=O)(=O)Cc1ccc2[nH]cc(CCCN3CCN(c4ncncc4OC)CC3)c2c1,Avitriptan,2D6-Substrate,negative
212,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
213,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,MK_0457_tozasertib,2D6-Substrate,negative
214,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
215,COc1ccc2[nH]c([S@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_R,2C19-Substrate,negative
216,CN(C)CCOC(c1ccccc1)c1ccccc1,Diphenhydramin,2D6-Substrate,negative
217,CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,Tiotixene,2D6-Inhibitor,negative
218,COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,3_methylether_estradiol,2C19-Substrate,negative
219,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
220,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
221,S=c1[nH]cnc2nc[nH]c12,Mercaptopurine,Solute_carrier_family_28_member_3-Substrate,negative
222,COc1ccc(CN2CCNCC2)c(OC)c1OC,Trimetazidine,-,negative
223,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,Anastrozole,19A-Inhibitor,negative
224,CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,Miocamycin,3A4-Inhibitor,negative
225,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,Pipamperone,GST-Inducer,negative
226,CNCCCN1c2ccccc2CCc2ccccc21,Desipramine,2E1-Inhibitor,negative
227,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone,-,negative
228,CC(C)(Oc1ccc(Cl)cc1)C(=O)O,Clofibric acid,-,negative
